§ 814.124. Institutional Review Board requirements.
220 words·~1 min read·
/us/cfr/t21/s§ 814.124·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)IRB approval. The HDE holder is responsible for ensuring that a HUD approved under this subpart is administered only in facilities having oversight by an Institutional Review Board
(IRB)constituted and acting pursuant to part 56 of this chapter, including continuing review of use of the device. In addition, a HUD may be administered only if such use has been approved by an IRB. If, however, a physician in an emergency situation determines that approval from an IRB cannot be obtained in time to prevent serious harm or death to a patient, a HUD may be administered without prior approval by an IRB. In such an emergency situation, the physician shall, within 5 days after the use of the device, provide written notification to the chairman of the IRB of such use. Such written notification shall include the identification of the patient involved, the date on which the device was used, and the reason for the use.
(b)Withdrawal of IRB approval. A holder of an approved HDE shall notify FDA of any withdrawal of approval for the use of a HUD by a reviewing IRB within 5 working days after being notified of the withdrawal of approval. [61 FR 33244, June 26, 1996, as amended at 63 FR 59221, Nov. 3, 1998; 82 FR 26349, June 7, 2017]
Connections1 cite this
Cited by 1 section
Citation graph
cites case law
§ 814.124
Institutional Review Board requirements.
Fed. Reg.×1
Cites 0Cited by 1 across 1 source